Melville, N.Y.-based Henry Schein touted the Cognivue as the 1st such device approved by the FDA.
The device is designed to allow practitioners to monitor current brain health and any future reversible dementia treatments which can be caused by sleep disorders, infection, systemic illness and mood disorders, these devices will constantly be seen in many dementia care homes to monitor the patients.
“We are excited to work with CAS to deliver advanced technology solutions that our customers can rely on for assessing serious health issues among patients. Our team is committed to not only leveraging our strong distribution network to help health care professionals gain greater access to this innovative technology, but also working with forward-thinking leaders such as CAS, to help practitioners focus on delivering high-quality patient care for dementia,” global medical group prez Bridget Ross said in a prepared statement.
The Cognivue system uses controlled visual stimuli on a computer screen to help in conducting a quantitative analysis of brain health to produce a composite score of overall brain functional integrity, Henry Schein said.
“Routine measurement of cognitive function should be available to all patients in order to detect discrepancies in brain functionality and then act on them as soon as possible. With Henry Schein Medical, our goal is to distribute the device to all the practitioners looking for a solution that makes the assessment of cognitive function as routine as having your blood pressure taken. Although an early diagnosis does not solve the cure, minimizing the toll dementia takes on patients – by addressing some of the potential causes associated with this condition – is the next best option,” device inventor and Cerebral Assessment Systems CEO Dr. Charles Duffy said in a press release.
In August, Henry Schein said its board of directors approved a 2-for-1 split of the company’s common stock.